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Abstract  
Patients admitted to critical care often experience dysglycaemia and high levels of insulin resistance, 
various intensive insulin therapy protocols and methods have attempted to safely normalise blood 
glucose (BG) levels. Continuous glucose monitoring (CGM) devices allow glycaemic dynamics to be 
captured much more frequently (every 2-5mins) than traditional measures of blood glucose and have 
begun to be used in critical care patients and neonates to help monitor dysglycaemia. In an attempt 
to obtain a better insight relating biomedical signals and patient status, some researchers have turned 
towards advanced time series analysis methods.  
In particular, Detrended Fluctuation Analysis (DFA) has been a topic of many recent studies in to 
glycaemic dynamics. DFA investigates the “complexity” of a signal, how one point in time changes 
relative to its neighbouring points, and DFA has been applied to signals like the inter-beat-interval of 
human heartbeat to differentiate healthy and pathological conditions.  
Analysing the glucose metabolic system with such signal processing tools as DFA has been enabled by 
the emergence of high quality CGM devices. However, there are several inconsistencies within the 
published work applying DFA to CGM signals. Therefore, this paper presents a review and a “how to” 
tutorial of DFA, and in particular its application to CGM signals to ensure the methods used to 
determine complexity are used correctly and so that any relationship between complexity and patient 
outcome is robust.   
Introduction  
Patients admitted to critical care often experience dysglycaemia and high levels of insulin resistance 
[1-7]. Hence, various intensive insulin therapy protocols and methods have attempted to safely 
normalise blood glucose (BG) levels in critical care patients. These studies achieved a range of positive 
and negative results with the most successful showing a correlation between lower blood glucose and 
improved patient outcomes [1-3, 8-12]. However, negative results [13, 14] and difficulty with 
increased nurse workload [15-17] have led to the idea that continuous glucose monitoring (CGM) 
devices might be a necessary tool to obtain better BG control and safety.  
 
In 2004 the first commercially available continuous glucose monitoring (CGM) device was released 
with FDA approval. CGM devices allow glycaemic dynamics to be captured much more frequently 
(every 2-5mins) than traditional measures of blood glucose. More recently, they have begun to be 
used in critical care patients and neonates to help monitor and monitor dysglycaemia [18-24].  
 
In an attempt to obtain a better insight into biomedical signals researchers have turned towards 
advanced time series analysis methods. In particular, Detrended Fluctuation Analysis (DFA) has been 
a topic of many recent studies into glycaemic dynamics [19, 25-27]. DFA investigates the “complexity” 
of a signal, how one point in time changes relative to its neighbouring points. In the simplest of terms 
DFA characterises the variability or “fuzziness” of a signal. DFA has been applied to inter-breath-
interval of human respiration, inter-beat-interval of human heartbeat and inter-stride-interval of 
human stride to differentiate between healthy and pathological conditions [28-34]. However, DFA 
requires a large, densely measured time series, limiting the signals it is applied to. Thus, analysing the 
glucose metabolic system with such signal processing tools as DFA is enabled by the emergence of 
high quality CGM devices that allow researchers to investigate if glucose complexity can be related to 
mortality [19, 25] or other outcomes.  
This paper presents a “how to” tutorial and review of work applying detrended fluctuation analysis to 
CGM signals. From the current published literature applying DFA to CGM signals it is evident that 
before any conclusions can be drawn regarding the relationships between glucose complexity and 
mortality, the methods used to determine complexity must be used correctly and robustly. That 
requirement necessitates a clear, consistent understanding of the methods and their applications. 
Prior works and tutorials on DFA are highly mathematical and some aspects of DFA have evolved over 
time. Thus the methods are not necessarily easily accessible to many outside these mathematical 
fields. Thus, this article seeks to bridge that accessibility gap.  
 
In particular this paper first introduces the terms, complexity, self-similarity, monofractal and 
multifractal. The paper then discusses how to determine if a signal is of the correct form for mono or 
multifractal analysis and the meaning of what each analysis produces. It also addresses the 
considerations needed for the correct implementation for DFA to be undertaken. Applications to CGM 
data from critical care patients are highlighted for clinical context and to demonstrate these concepts.  
  
What is Complexity, Self-similarity, Monofractal and Multifractal? 
 
The complexity of a signal is how one point in a time series relates to the next or the previous point in 
a time series. A signal with high complexity will have many rapid changes between neighbouring 
points, as shown in Figure 1 panel A, while a signal with low complexity will not, Figure 1 panel B. This 
complexity can be defined using monofractal DFA which defines complexity as one unit-less number, 
the Hurst co-efficient (H)  or multifractal DFA which defines complexity as a multifractal spectrum, 
Panels C and D. Which analysis, monofractal or multifractal, is appropriate for the signal depends on 
if the signal is mono or multifractal in structure.  
 
Figure 1: A comparison of a signal with low complexity (panel A)) and a signal with high complexity (panel B). The monofractal 
DFA was used to produce a Hurst coefficient for each signal, 1.23 and 1.83, respectively. Multifractal DFA was used to 
determine the multifractal spectrum for each signal, panel C and D, respectively. The width of this spectrum can also be used 
to define the complexity of each signal as was calculated as 1.09 and 1.39 respectively.    
 
If the signal is monofractal in structure it will be self-similar and this self-similarity will not change as 
time and space change [33, 35-37]. To be self-similar a signal must repeat it’s self on multiple scales. 
To visualise this repetition, think of a fern leaf, if you look closer at the fern leaf you will be able to see 
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many small fern leafs inside the big fern leaf and many fern leafs inside of these smaller fern leafs and 
so on and so forth. This is a self-similar or fractal structure. To undertake any type of detrended 
fluctuation analysis this self-similar structure must be apparent. If the signal is multifractal the signal 
will be self-similar but this will change as time and space changes and the complexity of the signal can 
no longer be defined by H it must be defined by the multifractal spectrum.  
There is no way to tell from just looking at a signal if it is self-similar, monofractal or multifractal. The 
step by step process to ensuring that a signal is self-similar and determining if a signal is multifractal 
or monofractal is outlined in the following section, DFA implementation. The section is followed by 
an analysis of the literature using DFA and results in a list of the key steps and requirements for using 
DFA correctly to ensure good results. 
Finally, for the purpose of this review, it should be noted that not every reader needs to be able to 
apply DFA to a signal or understand every equation in this paper. However, if they can understand the 
required signal characteristics and key steps to perform DFA correctly, then they will be in a far better 
place to interpret and evaluate DFA results or analyses in the literature. 
 DFA Implementation 
This section outlines the methods used by many different authors to carry out detrended fluctuation 
analysis for mono and multifractal biomedical signals. First, the key steps required to perform DFA, 
are summarised in Figure 2 and a step by step example implementing these key steps can be found in 
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Figure 2: Flow Chart of the process required to implement detrended fluctuation analysis. A step by step example is 
contained in the supplementary file, implementing these steps for a CGM signal.  
since it was first applied by Peng et al in 1994 [38]. Therefore, this section aims to highlight all the 
approaches that have been published to date to give insight and indicate the work necessary for DFA 
to become a trusted signal processing tool for CGM signals.    
Step 1 – Is the signal self-similar?  
When Peng et al [39] first introduced the concept of DFA to the biomedical field it was applied to easily 
and clearly measureable heartbeat time series where very large numbers of data points can be easily 
obtained. The authors then further detail the method in a separate journal article using a random walk 
describing the organisation of DNA nucleotides [38]. Importantly, both these signals display long range 
power-law correlations that indicate self-similarity across a number of decades of data [38, 39], which 
means the signal is exactly or approximately similar to a part of itself on many different time scales.  
To ensure fractal analysis can be carried out on a CGM signal three features of self-similarity must be 
evident [40]: 
1. At a scale 1/r when rescaled by rH X(rt) the signal looks the same as the original X(t) and is 
statistically indistinguishable from it.  
2. Fourier power spectrum of the signal -  if the frequency is doubled the power diminishes by 
the same fraction regardless of frequency  
3. Autocorrelation: Gaussian signals will show correlated or anti-correlated structuring, while in 
Brownian motion signals have neighbouring elements that are positively correlated. The 
equations for the correlation and correlation coefficients are thoroughly described in Eke et 
al. [40].  
However, the simplest way to check the self-similarity of a signal is to plot log (F(𝑠)) versus log(s) [35], 
as defined:  
𝑌(𝑖) =  ∑ [𝑥𝑘 −  〈𝑥〉],       𝑖 = 1, … , 𝑁
𝑖
𝑘=1                                    Equation 1 
𝐹(𝑠) =  √
1
𝑠
∑ (𝑌(𝑖) − 𝑦𝑠(𝑖))2
𝑠
𝑖=1                                                 Equation 2 
Where F(s) is the root mean square (RMS) of the variance between the time series, x, and the least 
squares fit for each segment, ys(i), and s is the segment sample size. If this plot displays a linear 
relationship the signal is self-similar [35], as shown in Figure 3. Self-similarity needs to be apparent 
over at least two decades of frequency before confidence in using fractal approaches can be assured 
[40]. 
 
Figure 3: The overall RMS F(s) plotted against s the segment sample size. The linear relationship over at least two 
decades (3 decades in this case) deems fractal analysis appropriate for this signal. 
 
Step 2 – Is the signal Monofractal or Multifractal? 
For Monofractal DFA to be valid the signal must have self-similarity that is independent of time or 
space [33, 35-37]. This means the Hurst coefficient must remain constant across all q-order statistical 
moments [35, 37]. More simply, the signal must be simple enough to be described by one fractal 
dimension. When the self-similarity of a time series changes with spatial and temporal variations, the 
signal is deemed to be multifractal [35].  
 
To determine if the self-similarity of a signal dependent on time and space we can plot the relationship 
of log(Fq(s)) versus log (s) and if the slope this this relationship changes with q-order statistical 
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When q = 0 a logarithmic averaging proceedure must be employed instead of Equation 4:  





𝑣=1 }              Equation 5 
 
 
Figure 4: An Example log(Fq(s)) versus log(s) plot. Note the linear relationship changes with q order statistical 
moments hence multifractal analysis is appropriate for this signal  
 
If unsure, it is wise to also plot the multifractal spectrum as it will clearly show if the signal is multi or 
monofractal, as shown in Figure 5, where the spectrum for a monofractal signal will be very narrow. 
The equations to generate the multifractal spectrum are defined:  
𝜏(𝑞) = 𝑞. 𝐻(𝑞) − 1      Equation 6 
ℎ(𝑞) = 𝜏′(𝑞)              Equation 7 
𝐷(𝑞) = 𝑞. ℎ(𝑞) −  𝜏(𝑞)        Equation 8 
Where q is the statistical moment and H(q) is the Hurst coefficient for that statistical moment. A plot 
of 𝐷(𝑞) vs. ℎ(𝑞) displays the mulitfractal spectrum.  
 
Figure 5: Example of multifractal spectrum that is produced from multifractal DFA. Note the monofractal signal produces a 
very narrow spectrum, indicating monofractal scaling is present and monofractal DFA is sufficient to characterise the scaling 
and correlation properties of the signal 
 
Step 3a and 3b – Signal length 
For the results of mono or multifractal DFA to be valid the signals must be of appropriate minimum 
length [33, 36, 40-43]. For monofractal DFA it is recommended that the signal be greater than 512 
points long for results with a bias and standard deviation of less than 0.05 [43]. However, to  have  a  
0.95  probability  of distinguishing  between  two  signals  with  true  Hurst coefficient  differing  by  
0.1,  more  than  32768  points  are required [43]. This number of points is feasible for a biological 
signal like heart beats, but is more difficult for CGM with typically 288 measurements a day. For 
Multifractal DFA results from signals less than 1000 measurements are to be viewed with caution [35]. 
The larger the sample size the larger the range of segment sizes to allowing both fast and slow 
fluctuations to be captured [35]. 
 
In comparison to the well-known Fast Fourier Transform (FFT), the signal length has similar 
implications. The FFT is a very common signal analysis tool using similarly long signals that provides a 
structured sum of sine wave terms to capture the shape of an arbitrary, assumed periodic signal. The 
length of data points used thus defines the resolution and accuracy of that decomposition from a 
general signal to a sum of sine waves at different frequencies.  
 
In contrast, DFA provides an arbitrary capture of a general signal as calculated from Equation (2), or 
Equations (3-5) for multifractal analysis, based on RMS variability from point to point, which is quite 
different than the structured sum of sine waves in a FFT. For DFA, as with the FFT, the length of the 
signal determines the level of resolution and accuracy. However, given their entirely different 
formulation, there is no direct analogy from FFT analysis of frequency content to the DFA analysis of 
point to point variability and complexity. 
 
Step 4a – Calculating the Hurst Coefficient  
 When Peng et al first used DFA in 1993 [39] they were not concerned with calculating the Hurst 
coefficient. They only aimed to prove the F(s) α sα power-law relationship existed for the scale 
invariant heart beat time series and how the value of α could appear markedly different for 
pathological and healthy conditions [39]. However, the signal type and resulting methods used vary 
between the first three publications from Peng et al on DFA [32, 38, 39]. Eke et al in 2002 [33] 
produced an overview of fractal complexity analysis. A more generic method for DFA was included in 
this paper, referencing Peng et al [38], which allows both Gaussian and Brownian type signals to be 
analysed and a Hurst coefficient obtained. The main computational steps for a successful DFA and 
calculation of the Hurst coefficient are:   
1. Integrate time series by summing and subtracting the mean creating a zero centred signal 
𝑌(𝑖) =  ∑ [𝑥𝑘 −  〈𝑥〉],       𝑖 = 1, … , 𝑁
𝑖
𝑘=1                                    Equation 1 
2. Choose sample size, s, and divide profile into Ns non-overlapping segments of equal length s 
3. Determine the trend for each segment, the root mean square (RMS) of the variance between 
the time series, x, and the least squares fit for each segment, ys(i) 
𝐹(𝑠) =  √
1
𝑠
∑ (𝑌(𝑖) − 𝑦𝑠(𝑖))2
𝑠
𝑖=1                                                 Equation 2  
4. Repeat Steps 2 and 3 for a range of segment sizes, s. Note that fast fluctuations in the series 
will influence F for segments with small sample sizes, whereas slow changing fluctuations will 
influence F for segments with larger sample sizes. Hence multiple scales necessary to capture 
both fast and slow fluctuations [35]. A rule of thumb for the number of segment sizes needed 
is >5 segments between 10 and N/2 [36].  
5. Plot F(s) vs. s and calculate the slope of the line, α 
6. Relate α to the Hurst coefficient  
a. if α < 1 then the signal is Gaussian α = H 
b. if α > 1 then the signal is Brownian α = H + 1  
To implement these steps, Ihlen [35] produced a self-sustained guide with downloadable Matlab files 
[35].  
 While [35] is mainly focused on multifractal DFA the code for monofractal DFA is included and 
explained. It is important to remember that DFA is not the only fractal analysis that characterises the 
complexity of a signal using the Hurst coefficient. There are many other ways of calculating H including 
scaled window variance methods, rescaled range analysis, dispersional analysis and maximum 
likelihood estimation [33, 36]. These analyses may produce a more accurate estimation of the Hurst 
coefficient for specific types of signals.  A summary of the benefits and drawbacks of these different 
type of fractal analysis has been produced by Delignieres et al [36]. 
 
Step 4b – Producing the Multifractal spectrum  
When the self-similarity of a time series changes with spatial and temporal variations, the signal is 
deemed to be multifractal [35], as described in Section 1, Step 2 and Figure 4. The complexity of such 
a sign is defined by a multifractal spectrum of power law exponents [35]. Kantelhardt et al [44] 
developed multifractal detrended fluctuation analysis (MFDFA) in 2002. The method to successfully 
implement MFDFA are well outlined in clear steps in this paper and have not evolved over time as 
they have for monofractal DFA. Readers are referred to [44] as a first step in understanding and 
undertaking MFDFA analysis. 
Some of the potential pitfalls in MFDFA include large errors induced in the multifractal spectrum if the 
RMS is close to zero as log(F) becomes infinitely small [35]. This issue can be resolved by eliminating 
RMS below a certain threshold, such as the precision of the measurement device that is recording the 
biomedical time series. Another issue is being able to distinguish if the signal being analysed is a 
random walk or noise like signal, and, therefore, if the signal requires transformation to a noise like 
signal before analysis. Eke et al [33] suggest first applying monofractal DFA to the signal and if the 
Hurst coefficient is between 0.2-1.2 the signal is a noise like signal and does not require 
transformation. However, if the signal is between 1.2-1.8 the signal is a random walk and needs to be 
differentiated before undertaking MFDFA. As mentioned previously in Step 1, it is also imperative to 
ensure the time series is self-similar.   
It is important to remember that MFDFA is not the only way of producing the multifractal spectrum 
to analyse the complexity of a signal. For example, there are multifractal analyses based on wavelet 
transforms, the results of which can be compared directly to MFDFA [28, 35, 45]. Performance of 
MFDFA has been shown to be comparable to the wavelet transform methods, unless the time series 
contains strong oscillatory or ramp like trends, where wavelet transform methods are preferred [35, 
45].  Hence, MFDFA is the main focus of this tutorial.   
The width, shape and location of the mulifractal spectrum can all be used to define the complexity of 
the time series being studied [35]. Differences in these variables between certain cohorts can be used 
to investigate relationships between the time series and the physiological phenomenon being studied. 
Elements of the mutlifractal spectrum have been used successfully to differentiate between certain 
heart diseases and the neural activity of different brain areas [46-48].  Therefore it is plausible to 
suggest that CGM signals could produce some indicator of mortality or significant metabolic or organ 
dysfunction from the differences in multifractal spectrum. However, the results from an initial 
investigation by Signal et al could not find a relationship between the multifactal spectrum and patient 
outcome [49].  
 
DFA, CGM and the ICU – Clinical Implementation  
The first study to investigate glucose complexity in critical care patients was Lundelin et al in 2010 
[25]. Monofractal DFA was applied to a cohort of 38 patients each with 1 CGM signal during a 24 hour 
period (n = 288 measurements). In this study Lundelin et al found mean Hurst coefficients of 1.49 and 
1.60 for survivors and non survivors, respectively (P=0.015).  Thus, Lundelin et al concluded that loss 
of complexity in a glycaemic time series, evaluated by DFA, correlates with higher mortality in the 
critically ill. However, the authors do not mention if the fractility of the signal was checked or 
questioned. In addition, to ensure the results of any monofractal DFA analysis are reliable with a bias 
and standard deviation of less than 0.05, the number of samples must be greater than 512 [41]. Any 
series with n < 258 cannot be considered reliable [41].  Each CGM trace analysed in Lundelin et al has 
only n = 288 measurements. Thus, the shortness of the time series used may significantly impact the 
conclusions drawn.  
 
In a follow up study to Lundelin et al, Brunner et al [19] applied monofractal DFA to a larger cohort of 
174 patients, with a larger time series of n= 710 for each patient. They found a mean Hurst coefficient 
for survivors of 1.52, which was lower than the mean coefficient for non-survivors of 1.61 (p = 0.01), 
matching the results in Lundelin et al. From these results they drew the same conclusion that loss of 
complexity in glycaemia time series, evaluated by DFA, correlates with higher mortality.  
 
However, as in [25] the authors of [19] do not mention if they investigated the fracticality of the CGM 
signals to ensure they were monofractal. Hence, it is not possible to conclude if monofractal DFA 
analysis is appropriate for this data set. In addition, in this study, there is a mix of CGMS gold 
retrospective devices (Medtronic Minimed, Northridge, CA, USA) and newer Guardian CGMS real time 
devices (Medtronic Minimed, Northridge, CA, USA). The calibration and signal processing for 
retrospective and real time devices is very different, where real time devices generally have a much 
higher noise content as they only have previous calibration values to guide blood glucose estimation. 
In contrast, retrospective devices fit a profile through all calibration measurements and “know” the 
future values at any point. This difference can lead to vastly different signals being produced by each 
device [50]. For example, Signal et al [49] found the Hurst coefficient varied more between 
retrospective and real time devices, than between survivors and non survivors.  
 This third study of glucose complexity in the critically ill, by Signal et al [49] did test the fractal structure 
of the CGM signals with n > 500.  It found that the CGM traces used for this analysis had a multifractal 
composition. Thus, monofractal DFA was not deemed an appropriate method to characterise the 
complexity of these signals. In contrast, multifractal analysis produces a spectrum of Hurst 
coefficients. Signal et al compared these spectrums, but found no association between complexity and 
mortality.  
 
Patients admitted to ICU are highly variable and can have a range of conditions or treatments that 
may impact on the accuracy of CGM, such as oedema, sepsis, cooling blankets and pressure around 
the sensor site [51, 52]. All of these factors affect sensor performance and will subsequently affect the 
results obtained from DFA. Also while inserting the CGM sensor in the subcutaneous layer is minimally 
invasive and generally safe from infection it can introduce increased noise and error within the output 
[21, 53-56]. Similarly, calibration differences or device sensor differences will change the glucose trace 
and the DFA results. It is important that any persons wanting to undertake DFA on CGM data from ICU 
patients, or other subjects, are aware of these potential confounding issues.  
Signal et al. [49] produced an interesting example of the potential effect of sensor performance on 
DFA results. A patient had three identical sensors inserted, all of which appeared to agree and track a 
similar glucose profile. However, the Hurst co-efficient and multifractal spectrum produced by each 
trace was markedly different. The authors also included an example where a patient had two identical 
sensors inserted, which did not show similarity in their output trace, but produced almost identical 
Hurst coefficients and multifractal spectrums.       
 
With these issues in mind, the authors have generated a list of clinical factors that should be 
considered for a study using DFA to assess the complexity of ICU patients CGM signals.  
1) Consistency of device type and calibration method [49]   
2) Consistency of sensor  insertion location on the body  
3) Avoiding highly oedematous or septic patients  as effects of such conditions are still under 
investigation or at least recording an “oedema score” so that like patients can be compared  
4) Diligence in recording medications and treatments that could affect sensor performance  
 
Conclusion  
This paper presents a step by step tutorial and review of detrended fluctuation analysis for use with 
continuous glucose monitoring signals from intensive care patients. From this review it is clear that 
before any conclusions can be drawn regarding the relationships between glucose complexity and 
mortality the methods used to determine complexity must be used correctly and robustly. In particular 
regarding the mathematical analysis of the data it is important the form of the data either, mono or 
multifractal, is considered to select the right analysis for the data. It is also imperative that the signal 
lengths are long enough to ensure reliable results. Furthermore for the correct clinical implementation 
consistent sensor type and location should be applied. Also important that users are consider and 
report the clinical factors which could impact the CGM signals and therefore DFA results such as 
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Supplementary File: A Worked Example 
 
The following example uses CGM data from an Ipro2 CGM device (Medtronic Minimed, Northridge, 
CA, USA) that was inserted into the abdomen of a healthy individual and worn for 6 days. Blood glucose 
was measured 4 times a day prior to meals and sleeping. These measurements were used to calibrate 
the device. Calibration BG measurements were taken using capillary finger stick measurements and 
the Abbott Optimum Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. 
 
Figure S1: CGM trace used for the worked example. 
Step 1 – Is the Signal Self Similar? 
Using Equation 1 and 2 a of plot log (F(𝑠)) versus log(s) was generated. Where segment sizes, s = [32, 
45, 64, 91, 128, 181, 256, 362, 512] were used to generate the non-overlapping segments of equal 
length, Ns required. The segment sizes where selected to allow both fast and slow fluctuations to be 
captured but to be no longer that half the signal (N = 1715).  




























 Figure S2: Plot of log (F(𝑠)) versus log(s) 
As shown in Figure S2 the relationship between log (F(𝑠)) and log(s) is linear hence the signal is self-
similar and therefore fractal analysis can be undertaken. The slope of the linear regression line, α, is 
1.21 thus the signal is Brownian or a random walk signal and H = α +1, 
 
Step 2 – Is the Signal multifractal or monofractal?  
Using Equation 3, 4 and 5 values of (𝐹𝑞(𝑠)) were generated for integer values of q, -5 < q < 5. The slope 
the (𝐹𝑞(𝑠)) for versus log (s) linear regression lines were calculated for each q, α(q). In Step 1 the signal 
was found to be a random walk hence H(q) = α(q) + 1. Also the signal was not integrate before this 
process was undertaken, a process that a Gaussian noise signal would require. H(q) was then plotted 
against q.   

















 Figure S3: H(q) as a function of q order 
This Figure S3 show how the linear relationship changes with q order statistical moments. Hence, 
multifractal analysis is appropriate for this signal 
 
Step 3 – Is the Signal long enough? 
For Multifractal signals the signal must be greater than 1000 data points for the results to be trust 
worth. This signal had N = 1715 so the signal length should not negatively impact the results.  
 
Step 4 - Implementation of DFA  
Equations 6, 7 and 8 were then employed to calculated D(q) and h(q) which when plotted against each 
other produce the multifractal spectrum.   
























 Figure S4: The multifractal Spectrum of the CGM trace 





0 0.5 1 1.5 2 2.5
-0.5
0
0.5
1
Multifractal spectrum
h(q)
D
(q
)
 
 
